Avidity Biosciences recently joined PPMD for a community webinar to share topline data from their EXPLORE44® clinical trial, which is assessing the safety and efficacy of the investigational therapy delpacibart zotadirsen (formerly AOC 1044, abbreviated as del-zota) in people living with Duchenne mutations amenable to exon 44 skipping. The Avidity team shared background information about del-zota and the EXPLORE44 study, provided an overview of results, and answered questions from the community.

Disclaimer: This webinar program is intended solely to provide information to the public. The views and opinions expressed as part of this webinar program do not necessarily state or reflect those of Parent Project Muscular Dystrophy (PPMD).